Abbreviations NAION: Nonarteritic anterior ischemic optic neuropathy RAPD: Relative afferent pupillary defect ODD: Optic disc drusen GLP-1 RA: Glucagon-like peptide-1 receptor agonist OCT: Optical coherence tomography ETDRS: Early Treatment Diabetic Retinopathy Study BMO: Bruchs membrane opening VA: Visual acuity IOP: Intraocular pressure GCA: Giant cell arteritis SAP: Standard automated perimetry MD: Mean deviation GCL: Ganglion cell layer EDI-OCT: Enhanced depth imaging optical coherence tomography VF: Visual field References Salvetat ML, Pellegrini F, Spadea L, Salati C, Zeppieri M
To attribute additional benefit to Tirzepatides GIP component, ocular expression and functionality of GIPR must be demonstrated
Embarking on the exploration of B12 Shots & B12 Injections: The Good, Bad, and Alternative
Clinical Evidence and What to Expect In This Article Understanding Jardiance and Its Effects on Body Weight How Jardiance Works and Why Weight Loss Occurs Clinical Trial Evidence on Weight Loss What to Expect: Timeline and Amount of Weight Loss Important Distinctions About Jardiance and Weight Management Factors That May Influence Weight Loss Results Common Side Effects vs Serious but Rare Side Effects Comparing Jardiance to Other Diabetes Medications Cost Considerations and Accessibility Who Should Consider Jardiance for Diabetes Management Setting Realistic Expectations References Understanding Jardiance and Its Effects on Body Weight Jardiance (empagliflozin) is a prescription medication primarily used to treat type 2 diabetes and reduce cardiovascular risks in certain patients
Strong regulatory oversight ensures high standards in cold-chain logistics, supporting safe distribution of injectable therapies